Click Here for 5% Off Your First Aladdin Purchase!

aficamten - 98%, high purity , CAS No.2364554-48-1

  • Moligand™
  • ≥98%
Item Number
A607438
Grouped product items
SKUSizeAvailabilityPrice Qty
A607438-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$59.90
A607438-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,334.90
A607438-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$279.90
A607438-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,001.90
A607438-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$799.90
A607438-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,119.90
View related series
Myosin

Basic Description

SynonymsAficamten|Aficamten [INN]|Aficamten [USAN]|2364554-48-1|CK-3773274|B1I77MH6K1|Aficamten [USAN:INN]|UNII-B1I77MH6K1|CHEMBL4847050|WHO 11544|1H-Pyrazole-4-carboxamide, N-((1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-|N-((1R)-5-(
Specifications & PurityMoligand™, ≥98%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™

Associated Targets

CYP1A2 Tchem Cytochrome P450 1A2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2D6 Tclin Cytochrome P450 2D6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2C8 Tchem Cytochrome P450 2C8 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2C19 Tchem Cytochrome P450 2C19 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP3A4 Tclin Cytochrome P450 3A4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2B6 Tchem Cytochrome P450 2B6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2C9 Tchem Cytochrome P450 2C9 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP3A5 Tclin Cytochrome P450 3A5 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methylpyrazole-4-carboxamide
INCHI InChI=1S/C18H19N5O2/c1-3-16-21-17(22-25-16)12-4-6-14-11(8-12)5-7-15(14)20-18(24)13-9-19-23(2)10-13/h4,6,8-10,15H,3,5,7H2,1-2H3,(H,20,24)/t15-/m1/s1
InChi Key IOVAZWDIRCRMTM-OAHLLOKOSA-N
Canonical SMILES CCc1onc(n1)c1ccc2c(c1)CC[C@H]2NC(=O)c1cnn(c1)C
Isomeric SMILES CCC1=NC(=NO1)C2=CC3=C(C=C2)[C@@H](CC3)NC(=O)C4=CN(N=C4)C
PubChem CID 139331495
Molecular Weight 337.38

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

12 results found

Lot NumberCertificate TypeDateItem
B2427173Certificate of AnalysisJan 22, 2024 A607438
B2427175Certificate of AnalysisJan 22, 2024 A607438
B2427176Certificate of AnalysisJan 22, 2024 A607438
B2427177Certificate of AnalysisJan 22, 2024 A607438
B2427178Certificate of AnalysisJan 22, 2024 A607438
B2427179Certificate of AnalysisJan 22, 2024 A607438
B2427180Certificate of AnalysisJan 22, 2024 A607438
B2427181Certificate of AnalysisJan 22, 2024 A607438
B2427182Certificate of AnalysisJan 22, 2024 A607438
B2427200Certificate of AnalysisJan 22, 2024 A607438
B2427201Certificate of AnalysisJan 22, 2024 A607438
B2427202Certificate of AnalysisJan 22, 2024 A607438

more

Related Documents

References

1. Argirò A, Zampieri M, Berteotti M, Marchi A, Tassetti L, Zocchi C, Iannone L, Bacchi B, Cappelli F, Stefàno P et al..  (2021)  Emerging Medical Treatment for Hypertrophic Cardiomyopathy..  J Clin Med,  10  (5): (589-97).  [PMID:33804412]
2. Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, Hwee DT, Wu Y, Wang J, Chin ER et al..  (2021)  Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy..  J Med Chem,  129  (3): (589-97).  [PMID:34606259]
3. Alsulami K, Marston S.  (2020)  Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases..  Int J Mol Sci,  21  (24): (589-97).  [PMID:33339418]

Solution Calculators